Omalizumab vs. placebo in the management of chronic idiopathic urticaria: a systematic review
Conclusions and implications of the main findings
Despite the limitations, it is considered that omalizumab 300 mg is effective in treating chronic idiopathic urticaria refractory to H1 antihistamines. Further studies are required to determine the duration of effective treatment.
Registration number of the systematic review
CRD42014010029 (PROSPERO. International Prospective Register of Systematic Reviews).
Source: World Allergy Organization Journal - Category: Allergy & Immunology Source Type: research
More News: Allergy | Allergy & Immunology | Clinical Trials | Databases & Libraries | Dermatology | Hives | Itchiness | Skin | Study | Xolair